Jane E. Henney (Chair) is the Home Secretary of the Institute of Medicine (IOM). She has held a series of senior health-policy leadership positions in the public sector. Beginning in 1980, Dr. Henney served for 5 years as the deputy director of the National Cancer Institute. She later joined the University of Kansas Medical Center as vice chancellor of health programs and, for 18 months, interim dean of the School of Medicine. She then served as deputy commissioner for operations of the US Food and Drug Administration (FDA), where she stayed until becoming the first vice president for health sciences at the University of New Mexico. In 1998, she was nominated by President Bill Clinton and confirmed by the Senate as the commissioner of the FDA. She served in that capacity until January 2001. After leaving FDA, she was appointed a senior scholar in residence at the Association of Academic Health Centers. From July 2003 until the beginning of 2008, she served as senior vice president and provost for health affairs at the University of Cincinnati. She continued her academic service to the university as a professor of medicine until 2013. Dr. Henney is a member of the Board of Directors of AmerisourceBergen Corporation and CIGNA in Philadelphia, Pennsylvania; Cubist Pharmaceuticals in Lexington, Massachusetts; the Monell Chemical Senses Center; the Commonwealth Fund; and the China Medical Board. She has received many honors and awards in her field, including election to the Society of Medical Administrators and honorary membership in the American College of Health Care Executives. She is a recipient of the Excellence in Women's Health Award from the Jacobs Institute, the Public Health Leadership Award from the National Organization of Rare Disorders, and, twice, the Public Health Service Commendation Medal. She is a member of IOM and has served as a member and chair of numerous National Academies committees. Dr. Henney earned an MD from Indiana University and
completed her subspecialty training in medical oncology at the M D Anderson Hospital and Tumor Institute and the National Cancer Institute.
John C. Bailar III is an emeritus professor of the University of Chicago. His research interests have included trends in cancer, assessment of such health risks as those posed by new chemicals, and misconduct in science. His expertise includes statistics, biostatistics, epidemiology, and environmental and occupational hazards. Dr. Bailar worked at the National Cancer Institute for 22 years, and he has held academic appointments at Harvard University, McGill University, and the University of Chicago. For 11 years, he was the statistical consultant and a member of the Editorial Board for The New England Journal of Medicine. He was a MacArthur Fellow from 1990 to 1995 and was elected to both the Institute of Medicine and the International Statistical Institute. Dr. Bailar has served as a member and as chair of many National Academies committees. His most recent committee work has included participation in the Committee on the Analysis of Cancer Risks in Populations near Nuclear Facilities—Phase I and the Committee to Review Studies of Possible Toxic Effects from Past Environmental Contamination at Fort Detrick. Dr. Bailar earned an MD from Yale and a PhD in statistics from American University.
Arthur P. Grollman is the Distinguished Professor of Pharmacological Sciences, the Evelyn G. Glick Professor of Experimental Medicine, and director of the Zickler Laboratory of Chemical Biology at the State University of New York at Stony Brook. His research interests focus on the biologic consequences of DNA damage as related to molecular mechanisms of replication, mutagenesis, and repair. Research in his laboratory has been instrumental in establishing the mechanism of action of the antitumor agent bleomycin and in defining the biochemical pathway that protects cells against mutations produced by oxidative DNA damage. He has received an American Cancer Society Scholarship Award and a MERIT award from the National Cancer Institute and has been elected to the Johns Hopkins Society of Scholars. Dr. Grollman earned an MD from the Johns Hopkins University School of Medicine.
Judith B. Klotz is an adjunct associate professor at the Drexel University School of Public Health and at the Rutgers School of Public Health. Previously, she was program manager of the cancer surveillance and environmental epidemiology programs of the New Jersey Department of Health. Her research interests are in epidemiologic studies of cancer incidence and reproductive outcomes, gene–environment interactions, evaluation of biologic exposures to environmental contaminants, and the application of health risk assessment and epidemiology to public policy. Dr. Klotz served as a member of the National Research Council Committee to Review Possible Toxic Effects from Past Environmental Contamination at Fort Detrick and Subcommittee on Fluoride in Drinking Water. She received her DrPH in environmental health sciences from Columbia University School of Public Health.
Xiaomei Ma is an associate professor in the Department of Chronic Disease Epidemiology of the Yale School of Public Health. Her research interests are in the epidemiology of hematologic malignancies, including leukemia, myelodysplastic syndromes, and lymphoma. Specifically, she is interested in environmental and genetic factors in the etiology of childhood leukemia, the outcomes of myelodysplastic syndromes, and methodologic issues in the design of various types of epidemiologic studies. Dr. Ma served as a member of the National Research Council Committee on Contaminated Drinking Water at Camp Lejeune. She received a PhD in epidemiology from the University of California, Berkeley.
John B. Morris is the Board of Trustees Distinguished Professor, a professor of pharmacology and toxicology in the Department of Pharmaceutical Sciences, and interim dean of the University of Connecticut School of Pharmacy. His research focuses on toxicity of inhaled irritant vapors, irritants and asthma, regional uptake and metabolism of inspired vapors, physiologically based pharmacokinetic modeling, and risk assessment. Dr. Morris has served on the editorial boards of Toxicological Sciences and Inhalation Toxicology and on advisory panels for the National Institutes of Health, the US Environmental Protection Agency, and the Department of Energy. He has also served as a member of the National Research Council Committee on Emergency and Continuous Exposure Guidance Levels for Selected Submarine Contaminants. Dr. Morris earned a PhD in toxicology from the University of Rochester.
Charles G. Plopper is professor emeritus of the School of Veterinary Medicine of the University of California, Davis. His research interests include pulmonary cellular and developmental biology, injury and repair responses of lung cells to inhaled and bioactivated toxicants, lung toxicology, lung cellular pathobiology, and cell biology and anatomy. Dr. Plopper has been an adviser to the National Institutes of Health, the US Environmental Protection Agency, and the California Environmental Protection Agency, and he has served as a visiting scientist at the National Cancer Institute. He has been recognized for career achievements by the Society of Toxicology and received the Pfizer Award for Research Excellence twice at the University of California, Davis. He has also received the Norden Distinguished Teaching Award from the University of California, Davis, School of Veterinary Medicine and the Meritorious Teaching Award from the University of Hawaii. Dr. Plopper earned a PhD in anatomy from the University of California, Davis.
Stephen M. Roberts is a professor and director of the Center for Environmental and Human Toxicology in the College of Veterinary Medicine of the University of Florida. He previously served on the faculties of the College of Pharmacy of the University of Cincinnati and the College of Medicine of the University of Arkansas. His research interests include mechanisms of drug and chemical toxicity, cell defense mechanisms against toxicity, toxicokinetics, bioavailability of environmental contaminants, risk assessment, and novel gene-therapy approach-
es for cancer. Dr. Roberts earned a PhD in pharmacology from the University of Utah College of Medicine.
Ivan Rusyn is a professor in the Department of Environmental Sciences and Engineering of the School of Public Health of the University of North Carolina (UNC) at Chapel Hill. He directs the Laboratory of Environmental Genomics and the Carolina Center for Computational Toxicology of the Gillings School of Global Public Health at UNC-Chapel Hill. He is a member of the Lineberger Comprehensive Cancer Center, the Center for Environmental Health and Susceptibility, the Bowles Center for Alcohol Studies, and the Carolina Center for Genome Sciences. Dr. Rusyn's laboratory focuses on the mechanisms of action of environmental toxicants, the genetic determinants of susceptibility to toxicant-induced injury, and computational toxicology. He has served on several National Research Council committees and is currently a member of the Committee on Use of Emerging Science for Environmental Health Decisions and the Committee on Toxicology. Dr. Rusyn received his MD from the Ukrainian State Medical University in Kiev and his PhD in toxicology from UNC-Chapel Hill.
Elaine Symanski is an associate professor and director of the Southwest Center for Occupational and Environmental Health of the University of Texas Health Science Center at Houston. Her research interests include development and application of quantitatively based approaches for evaluating occupational and environmental exposures, retrospective exposure assessment for workplace contaminants, and investigation of health effects associated with exposure to occupational and environmental contaminants. She served as a member of the National Research Council Committee on Contaminated Drinking Water at Camp Lejeune. Dr. Symanski received her PhD in environmental sciences and engineering from the University of North Carolina at Chapel Hill.
Weiqiang (John) Zhao is an assistant professor of pathology and director of the Pathology Core Facility at Ohio State University. His research interests include the investigation of molecular mechanisms of leukemogenesis, the determination of prognostic genetic abnormalities of leukemia and lymphoma cells, and the elucidation of host genetic determinates of treatment response and late effects. He is certified by the American Board of Pathology, the American Board of Hematopathology, and the American Board of Molecular Genetic Pathology. Dr. Zhao earned an MD from the Hunan Medical University in Changsha, China, and a PhD in molecular and cell biology from Tulane University.